Xtandi (Enzalutamide) is commonly used to provide supportive systemic control in men with advanced prostate cancer, assisting with symptomatic management across key therapeutic domains.

Treating Advanced Prostate Cancer: Uses and Benefits

This medication is generally applied across conditions characterized by periods of heightened symptoms where prostate cancer has progressed. It is relevant for several specific scenarios, including when the disease is Castration-Resistant (CRPC), when it is metastatic (mCSPC or mCRPC), and in cases of high-risk biochemical recurrence where the cancer has not yet spread. The treatment provides support that may assist patients with symptom management and supports general well-being during symptomatic phases, offering relief in situations involving heightened systemic burden.

“It is commonly used when symptoms relate to active disease, such as a rising Prostate-Specific Antigen (PSA) level, and when supportive systemic management is a relevant goal.”

This systemic support may assist with maintaining functional stability. Furthermore, it plays a role in managing the risk of developing severe, painful skeletal-related events, such as pathological bone fractures, which assists with maintaining functional stability and comfort during symptomatic phases.

---

Quick Fact: Relief for Disease Progression The medication is considered relevant for easing the overall symptom load as it may assist with managing symptoms related to heightened physiological activity, especially in men whose disease no longer responds to initial hormone therapy.

Xtandi (enzalutamide) is an androgen receptor inhibitor indicated only for the treatment of adult men with approved prostate cancer indications.

---

Contraindications (Who Must Not Use)

Official regulatory labeling dictates that Xtandi is contraindicated in two main groups:

• Women who are or may become pregnant due to the high risk of fetal harm and potential pregnancy loss.
• Patients with a known hypersensitivity (severe allergic reaction) to enzalutamide or any of its excipients.

---

Eligibility Constraints and Special Populations

Use is not established in the pediatric population (patients under 18 years of age). For adult men, several conditions require caution or special consideration:

Population/Condition	Regulatory Status
Severe Renal Impairment	Caution is advised; use is not formally studied.
Hepatic Impairment	No dose adjustment is typically necessary for mild to severe impairment.
Seizure Risk Factors	Use requires caution; permanent discontinuation is mandatory upon developing a seizure.
Reproductive Potential	Male patients with partners of reproductive potential must use effective contraception during treatment and for 3 months after the last dose.

Eligibility is also contingent on the permanent discontinuation of the drug if a patient develops certain serious events, such as Grade 3–4 ischemic heart disease.

Interactions with Other Medicines and Products

Xtandi (Enzalutamide) is officially documented as having a significant pharmacokinetic interaction profile, primarily through its ability to alter the exposure of other medicinal products.

Documented Interaction Patterns

Interaction Type	Affected Substances	Official Outcome/Restriction
Enzyme Induction	Substrates of CYP3A4, CYP2C9, and CYP2C19	Decreases plasma exposure, raising the risk of therapeutic failure for the co-administered drug.
Transporter Induction	Substrates of P-glycoprotein (P-gp)	Decreases plasma exposure of the co-administered drug.
Metabolism Inhibition (on Xtandi)	Strong CYP2C8 Inhibitors (e.g., Gemfibrozil)	Increases Enzalutamide plasma exposure, increasing the risk of adverse reactions. Avoid co-administration if possible.

Other Documented Constraints

Enzalutamide's exposure is officially decreased by strong CYP3A4 inducers (e.g., Rifampin). Consequently, co-administration with the herbal product St. John’s Wort is advised to be avoided. The medicine may be taken with or without food, as food does not alter the dosage requirements or safety profile. For patients with severe hepatic impairment (Child-Pugh Class C), the official labeling contains specific considerations due to reduced elimination of Enzalutamide and its active metabolite.

Multi-Stage Androgen Receptor Inhibition

Xtandi's primary action is the selective silent antagonism of the Androgen Receptor (AR), the protein that androgens bind to. This mechanism is a multi-stage blockade of the AR signaling pathway. The drug binds with high affinity to the receptor, which prevents androgen activation, and actively suppresses the three critical steps required for signaling: nuclear translocation (movement into the cell nucleus), DNA binding (interaction with the cell's genetic code), and co-activator recruitment. This molecular inhibition leads to the downregulation of the cell's androgen-regulated gene expression.

---

Mechanistic Cascade and Biological Constraints

The suppression of the AR's transcriptional program is the physiological consequence that limits the proliferation of hormone-sensitive cells. However, this mechanism is subject to biological constraints, such as the emergence of AR splice variants (like AR-V7) that lack the drug's binding site, allowing the receptor to remain constitutively active and bypass the AR antagonism. Additionally, the drug exhibits an off-target activity by modulating GABAA receptors in the central nervous system (CNS), altering inhibitory neurotransmission.

How to Use Xtandi (Enzalutamide) — Administration Guidelines

This section summarizes the instructions for taking Xtandi (Enzalutamide), providing a framework for its administration.

---

Instruction	Detail
Route of Administration	Oral use only.
Standard Dosing	Recommended Dose: 160 mg (taken as multiple units).
Frequency and Timing	Once daily (a single oral daily dose).
Intake Condition	Can be taken with or without food.

---

The standard regimen for Xtandi is a 160 mg dose taken by mouth once daily. This dose is typically achieved using four 40 mg soft gelatin capsules or a combination of 40 mg and 80 mg film-coated tablets. The medication must be swallowed whole with water and should never be chewed, cut, or crushed.

Administration is generally continuous, designed to proceed until there is documented disease progression or the onset of unacceptable side effects. For most therapeutic scenarios, this medicine is used concurrently with a gonadotropin-releasing hormone (GnRH) analog or following surgical orchiectomy.

Dosing is standardized, with specifications that no routine dose adjustment is necessary for older adults or for patients with mild to severe hepatic impairment. In the event that a dose is missed for a full 24-hour period, the user should not take an extra dose to compensate, but instead resume the normal daily dose on the following scheduled day.

Research Evidence / Overview of Studies for Xtandi (Enzalutamide)

---

Evidence for use in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

The research examined this medicine in men with mCRPC, a condition involving periods of heightened symptoms. Studies were conducted both in men who had previously received chemotherapy and those who had not. These were primarily large, international randomized controlled trials (RCTs) comparing the medicine (alongside standard care) against a placebo. The studies monitored important outcomes such as Overall Survival (OS) and Radiographic Progression-Free Survival (rPFS). Studies reported measurements of Overall Survival and Radiographic Progression-Free Survival in the group receiving the medicine that were longer compared to the placebo group. Trials reported data on the time until patients needed to start subsequent treatments with a tendency toward a difference in duration observed in the medicine groups. Research also examined patient-reported outcomes.

Evidence for use in Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

The core evidence for this use comes from a major Phase 3 RCT involving men whose cancer had not spread but whose PSA levels were rising quickly—a condition marked by functional limitations. The primary outcome the research examined was Metastasis-Free Survival (MFS). The study data show patterns related to Metastasis-Free Survival measurements that were longer in the group that received the medicine compared to the placebo group. Later follow-up analyses findings indicate that Overall Survival measurements were longer in the medicine group.

---

What is Still Uncertain About Xtandi’s Research Evidence

Research highlights what is known — and what is still uncertain. Comparative evidence is lacking from head-to-head randomized trials that directly compare this medicine against all other modern hormonal agents used to treat prostate cancer. While Overall Survival findings are reported across most indications, the follow-up durations were limited in some early reports, and long-term effects are not fully established beyond the duration of the trial itself. The early results apply only to the populations studied, meaning the exclusion of men with certain neurological conditions creates a gap where data for those specific groups remain insufficient.

Key Studies & References

1. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer (EMBARK Trial Final Analysis)

Common questions about Xtandi (FAQ)

Q: What is the typical timeframe before knowing if Xtandi is working?

Studies and official information indicate that it takes approximately one month for enzalutamide to reach stable (steady state) concentrations in the blood after starting the daily dosing regimen. Regulatory information indicates that the full therapeutic response is monitored by a doctor following the achievement of stable blood levels. The time to clinical response is monitored by a doctor based on standard measures.

Q: Does Xtandi cause hair loss?

Official product information notes that hair loss is a side effect that has been reported, but it is considered to be a rare event. It does not fall into the common or very common categories of documented side effects observed during clinical trials.

Q: Why does Xtandi sometimes cause fatigue?

Fatigue and weakness are documented as very common side effects. The mechanism of the drug involves not only blocking the androgen receptor but also an off-target activity in the central nervous system (CNS). This CNS effect, which involves inhibiting GABA-gated chloride channel activity, is associated with neurological and related side effects like fatigue.

Q: Does Xtandi interact with over-the-counter pain relievers like ibuprofen?

According to official regulatory documents, enzalutamide is a strong inducer of metabolic enzymes, including CYP2C9. This means it can speed up the breakdown of other medicines, potentially decreasing their effectiveness. Some common over-the-counter pain relievers are processed by this same enzyme and may be affected, which may require medical oversight if co-administered.

Q: What happens if I forget to take my Xtandi for a few days?

Official guidance explicitly addresses missing the dose for one whole day (resuming the usual dose the next day without compensating). If a patient misses the dose for a longer duration, such as a few days, the official documents contain a standard protocol for temporary withholding and resuming the dose in situations of toxicity, which is administered with medical guidance.

Q: Does Xtandi interact with blood thinners?

Yes, official labeling notes that enzalutamide may decrease the plasma exposure of drugs that are substrates of the CYP2C9 enzyme. This includes blood thinners such as warfarin. Additional monitoring of the International Normalized Ratio (INR) is indicated by the official labeling if they are co-administered.

Q: Are there any specific lifestyle changes needed while on Xtandi?

The official labeling notes the risk of seizure and cautions that activities where a sudden loss of consciousness could cause serious harm are often avoided. Furthermore, the official labeling recommends management of cardiovascular risk factors, such as high blood pressure.

Q: Does Xtandi interact with common diabetes medications?

The drug is a strong inducer of multiple metabolic enzymes, including CYP2C8, CYP2C9, and CYP3A4. Many common diabetes medications are broken down by these enzymes. Therefore, co-administration may reduce the concentration and, potentially, the effectiveness of the diabetes medication.

Q: How do doctors monitor the effectiveness of Xtandi?

Effectiveness is monitored clinically until there is documented disease progression or unacceptable toxicity. The clinical trials used endpoints such as Overall Survival (OS), Radiographic Progression-Free Survival (rPFS), and Prostate-Specific Antigen (PSA) levels.

Q: Does Xtandi affect cholesterol levels?

The official labeling advises optimizing the management of cardiovascular risk factors, such as dyslipidemia (abnormal cholesterol or fat levels in the blood). This indicates that the medication may affect these factors, which suggests that monitoring in this area may be clinically relevant.

Q: Why is it important to avoid grapefruit juice while on Xtandi?

Official patient education materials caution that grapefruit and grapefruit juice may interact with enzalutamide, and therefore avoidance is advised in the product information.

Q: Can Xtandi affect fertility?

Due to the risk of harm to an unborn baby, regulatory constraints state that male patients with partners of reproductive potential are required to use effective birth control (contraception) during treatment and for three months after the last dose. This requirement addresses reproductive risk.

Q: Is it true that Xtandi may cause confusion or memory problems?

Yes, official regulatory safety data reports adverse events related to cognitive function. These include memory impairment, cognitive disorder, and disturbance in attention. The official labeling provides information on the risk of developing these and other neurological events.

How to Store and Dispose of XTANDI (Enzalutamide)

XTANDI must be stored according to specific regulatory conditions to maintain its stability and effectiveness.

Storage Requirements

Condition	Requirement
Temperature	Controlled room temperature: 20 C to 25 C (68 F to 77 F). Do not refrigerate or freeze.
Container	Store in the original container and keep the container tightly closed.
Environment	Protect from light and moisture (store in a dry place).
Child Safety	Keep out of the sight and reach of children.

Handling and Disposal

Xtandi capsules and tablets should not be crushed, opened, or dissolved. If a capsule is accidentally broken, the spilled material must be immediately wiped up and discarded. Unused or expired medication must not be disposed of in household trash or wastewater. Disposal should occur via a drug take-back program or as specifically instructed by a pharmacist or local authority for pharmaceutical waste.